Securities code: Sansure Biotech Inc(688289) securities abbreviation: Sansure Biotech Inc(688289) Announcement No.: 2022029 Sansure Biotech Inc(688289)
Announcement on resolutions of the second meeting of the first board of supervisors in 2022
The board of supervisors and all supervisors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
1、 Meetings of the board of supervisors
Sansure Biotech Inc(688289) (hereinafter referred to as “the company”) held the second meeting of the first board of supervisors in 2022 on April 18, 2022. Three supervisors should attend the meeting and three actually attended the meeting. The meeting was presided over by Ms. Tan Yi, chairman of the board of supervisors. The notice, convening and deliberation procedures of this meeting comply with the relevant provisions of the company law and the articles of association.
2、 Deliberation at the meeting of the board of supervisors
After deliberation by the attending supervisors, the following proposals were unanimously adopted:
1. Deliberated and adopted the profit distribution plan for Sansure Biotech Inc(688289) 2021
Content: according to the audit confirmation of Zhongshen Zhonghuan Certified Public Accountants (special general partnership), the net profit attributable to the shareholders of the listed company in 2021 was 224269639558 yuan, and the distributable profit of the parent company was 378010491461 yuan as of December 31, 2021.
The annual profit distribution plan for 2021 is as follows: the company plans to distribute a cash dividend of 3.75 yuan (including tax) to all shareholders for every 10 shares based on the total share capital of the company registered on the equity registration date of equity distribution minus the shares in the company’s special securities repurchase account. As of April 18, 2022, the total share capital of the company is 40000000000 shares. After deducting 4791299 shares in the special securities account for repurchase, the total cash dividend to be distributed is 14820326288 yuan (including tax).
For the long-term consideration of shareholders’ interests, the plan comprehensively considers the overall strategic layout and capital demand of the company, so as to ensure the sustainable and stable development of the company’s operation. The undistributed profits retained by the company will be used for the company’s new product R & D investment, platform enterprise building, industrial chain extension, accelerating international layout, talent team construction and other strategic planning projects, as well as the cash source of profit distribution in the future.
Voting result: 3 affirmative votes; No negative vote; There were no abstentions.
This proposal needs to be submitted to the general meeting of shareholders of the company for deliberation.
2. The annual report and summary of Sansure Biotech Inc(688289) 2021 were reviewed and adopted
Content: audited by Zhongshen Zhonghuan Certified Public Accountants (special general partnership), the company’s 2021 annual report and its summary have been prepared, and all supervisors have confirmed the annual report data. The content of the report is true, accurate and complete, and there are no false records, misleading statements or major omissions.
Voting result: 3 affirmative votes; No negative vote; There were no abstentions.
This proposal needs to be submitted to the general meeting of shareholders of the company for deliberation.
3. The proposal of Sansure Biotech Inc(688289) on renewing the appointment of the audit institution in 2022 was reviewed and approved. The content: in order to ensure the continuity of audit business, comprehensively consider the audit quality and service level, and based on the good cooperative relationship between the two sides, it was nominated by the Audit Committee of the company in accordance with the relevant provisions of the articles of association and the current regulatory requirements, The company plans to renew the appointment of Zhongshen Zhonghuan Certified Public Accountants (special general partnership) as the company’s audit institution in 2022 until the end of the general meeting of shareholders in 2022.
Voting result: 3 affirmative votes; No negative vote; There were no abstentions.
This proposal needs to be submitted to the general meeting of shareholders of the company for deliberation.
4. The special report on the deposit and actual use of raised funds in Sansure Biotech Inc(688289) 2021 was reviewed and adopted
Content: in accordance with the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (CSRC announcement [2022] No. 15) issued by the CSRC and the guidelines for the self discipline supervision of listed companies on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation issued by the Shanghai Stock Exchange, The special report truthfully reflects the annual deposit and actual use of the raised funds of the company as of December 31, 2021 in all major aspects.
Voting result: 3 affirmative votes; No negative vote; There were no abstentions.
5. Deliberated and adopted the Sansure Biotech Inc(688289) 2021 annual social responsibility report
Content: during the reporting period, the company earnestly implemented environmental protection, actively fulfilled social responsibilities, and continuously improved the corporate governance structure. The company has prepared the 2021 social responsibility report in accordance with the Listing Rules of Shanghai Stock Exchange Kechuang board, the self regulatory guidelines for companies listed on Shanghai Stock Exchange Kechuang board No. 1 – standardized operation and other relevant documents, combined with the characteristics of the industry to which the company belongs and the actual situation of the company’s performance of social responsibility during the reporting period. Voting result: 3 affirmative votes; No negative vote; There were no abstentions.
6. The work report of the board of supervisors for Sansure Biotech Inc(688289) 2021 was reviewed and adopted
Content: in strict accordance with the company law, the articles of association, the rules of procedure of the board of supervisors and other laws and regulations as well as the relevant systems of the company, all members of the board of supervisors of the company performed their duties diligently and independently, supervised and reviewed the operation, financial situation, production and operation and major decision-making matters of the company, put forward relevant opinions and suggestions, promoted the standardized operation of the company and actively safeguarded the rights and interests of all shareholders.
Voting result: 3 affirmative votes; No negative vote; There were no abstentions.
This proposal needs to be submitted to the general meeting of shareholders of the company for deliberation.
7. The proposal of Sansure Biotech Inc(688289) on the remuneration plan of supervisors in 2022 was deliberated and adopted. The content: in accordance with the relevant provisions of the company law of the people’s Republic of China, the governance standards of listed companies, the Listing Rules of Shanghai Stock Exchange on the science and innovation board and the articles of association, and in combination with the remuneration level, annual operation status and post responsibilities of the company’s industry and region, The company formulates the remuneration plan for supervisors in 2022 as follows: supervisors who hold actual positions in the company receive remuneration according to their actual positions; Supervisors who do not hold actual positions in the company will not receive remuneration.
Voting result: 3 affirmative votes; No negative vote; There were no abstentions.
This proposal needs to be submitted to the general meeting of shareholders of the company for deliberation.
8. The first quarter report of Sansure Biotech Inc(688289) 2022 was reviewed and adopted
Content: the company’s first quarter report of 2022 has been prepared, and all supervisors have confirmed the data of the first quarter report. The content of the report is true, accurate and complete, and there are no false records, misleading statements or major omissions.
Voting result: 3 affirmative votes; No negative vote; There were no abstentions.
It is hereby announced.
Sansure Biotech Inc(688289) board of supervisors April 19, 2022
